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INTRODUCTION
Betulinic acid [3β-hydroxy-lup-20(19) lupean-
28-carbonic acid] is a lupine-type triterpene 
which was first isolated in 1948 from the bark 
of the London plane tree (Platanus acerifolia) 
(Jung & Duclos, 2006).  It can also be found 
abundantly in the bark of white birch (Betula 
alba) or chemically derived from betulin 
(Csuk et al., 2006).  Betulin is an abundant 
naturally occurring triterpene and it is found 
predominantly in bushes and trees.  Both betulin 
and betulinic acids possess a wide spectrum 
of biological and pharmacological activities 
(Alakurtti et al., 2006).
Jeremias et al. (2004) found that betulinic 
acid induced specific cell death of more than 75% 
in the primary glioblastoma multiforme cells in 
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ABSTRACT
Betulinic acid and its derivatives showed cytotoxicity against variety of tumour and cancer cell lines comparable 
to some clinically used drug.  In the present study, the immunomodulatory effects of betulinic acid, isolated from 
the roots of Melaleuca Cajuputi, was studied.  Immunomodulatory effect was evaluated by using lymphocytes 
proliferation assay on mice splenocytes, thymocytes and human peripheral blood mononuclear cells (PBMC), 
while the cell cycle progression of betulinic acid treated PBMC was also studied by using flow cytometer. 
The production of human interleukin-2 (IL-2) and human inteleukin-12 (IL-12) cytokines was also assessed 
using enzyme-linked immunosorbent assay (ELISA).  The results showed that betulinic acid was able to 
stimulate the proliferation of mice thymocytes, splenocytes and human PBMC in a time and dose-dependent 
manner.  Meanwhile, betulinic acid treated immune cells were proliferated well at lower concentration (7.5 
µg /mL), but growth inhibition occurred at a higher concentration (30 µg /mL).  The findings obtained from 
the cell cycle analysis exhibited the proliferation effect of betulinic acid on PBMC, whereby 43.66 ± 2.60% 
and 42.83 ± 2.40% of the cells entered G2/M phase after 24h and 48h, respectively.  Moreover, betulinic acid 
also induced extracellular IL-2 and IL-12 production.  This finding demonstrates that betulinic acid acts as an 
immunomodulatory agent that may be useful in enhancing immune system.
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vitro at substantially higher rate than established 
cytotoxic drugs vincristine.  When betulinic acid 
was compared for in vitro efficiency against 
several leukaemia cell lines with conventionally 
used cytotoxic drugs, the acid was found to be 
more active than 9 out of 10 standard therapeutics 
(Ehrhardt et al., 2004).  In fact, betulinic acid 
also has indicated selective apoptotic activity 
toward melanoma cells (Pisha et al., 1995) as 
well as the tumour cells of neuroectodermal 
origin (Fulda et al., 1998) and B16 (Liu et 
al., 2004).  Betulinic acid induced apoptosis 
is mediated by a decrease in mitochondrial 
permeability due to the release of mitochondrial 
cytochrome c into the cytosol (Fulda & Debatin, 
2005), the formation of reactive oxidative 
species and the activation of crm-A-insentive 
caspase activity (Wick et al., 1999) rather 
than through a ligand/receptor system.  When 
betulinic acid was used in combination with 
anticancer drug vincristine, it showed synergistic 
cytotoxic effect on the growth and metastases of 
melanoma cells (B16F10) in vivo (Sawada et al., 
2004).  Moreover, betulinic acid has shown to be 
non-toxic up to 500 mg/kg body weight in mice 
(Pisha et al., 1995), as well as also cytotoxic on 
medullablastoma (Daoy), glioblastoma (A172) 
and melanoma (Mel-Juso) cancer cells without 
effecting normal human fibroblast (Fulda & 
Debatin, 2005).
Bes ides ,  be tu l in i c  ac id  was  a l so 
found to inhibit the replication of human 
immunodeficiency virus (HIV) (Zhou et al., 
2004; Hashimoto et al., 1997).  Several betulinic 
acid derivatives are also very potent and 
highly selective inhibitor of HIV-1 depending 
on their specific side-chain modification of 
the compounds.  These compounds function 
by inhibiting HIV fusion, or as recently 
demonstrated, by interfering with a specific 
step in HIV-1 maturation (Aiken & Chen, 
2005).  Moreover, betulinic acid was able to 
activate macrophage to produce two groups of 
protein mediators for inflammation including 
interleukin-1β and tumour necrosis factor-α (Yun 
et al., 2003).  In addition, betulinic acid also 
possesses anti-malaria and anti-inflammatory 
activities.  Furthermore, betulinic acid was found 
to be active against chloroquine sensitive (T9-
96 strain) and resistant (K1 strain) Plasmodium 
falciparum (Alakurtti et al., 2006).
Undoubtedly, betulinic acid exhibited 
various pharmacological activities.  Although 
comprehensive tests have been carried out to 
study the cytotoxic, anti-malaria, antivirus and 
even immunomodulatory effect (on macrophage) 
of this compound, not many studies have been 
addressed the immunomodulatory activity 
of betulinic acid towards mice and human 
lymphocyte in vitro.  Thus, the present study was 
carried out to investigate the immunomodulatory 
effect of betulinic acid which had successfully 
been isolated from the bark of Melaleuca cajuputi 
on mice splenocyte, thymocytes proliferation, 
human peripheral blood mononuclear cells 
(PBMC) proliferation, as well as human PBMC 
cell cycle progression and cytokine (Interleukin 
2 and 12) induction. 
MATERIALS AND METHODS
Materials
Betulinic acid, extracted from the bark of 
Melaleuca cajuputi, was supplied by Prof. Dr. 
Faujan Ahmad, from Department of Chemistry, 
Faculty of Science, Universiti Putra Malaysia. 
The pure compound of betulinic acid appears 
as a white solid, with melting point of 295-
297oC.  It was isolated from Melaleuca sp. and 
was chromatographed on a silica gel column 
with increasing polarity of chloroform and 
methanol solvent system (Ahmad et al., 1997). 
The concentrated compound was dissolved in 
dimethylsulphoxide (DMSO) (Sigma, USA) to 
obtain a stock solution of 10 mg/mL.  Later, a 
sub-stock solution of 0.06 mg/mL was prepared 
by diluting 6 μL of the stock solution into 994 μL 
serum-free culture medium, RPMI 1640 (Sigma, 
USA) (note that the percentage of DMSO in the 
experiment should not exceed 0.5%).  Then, the 
stock and sub-stock solutions were both stored 
at 4°C.
Concanavalin A (Con A) (Sigma, USA), 
lipopolysaccharide (LPS) (from Salmonella 
enteritidis) (Sigma, USA) and Pokeweed 
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mitogen (PWM) (1 mg/mL) were used as 
a  pos i t ive  cont ro l .   This  commercia l 
immunomodulator was prepared by dissolving 
with RPMI 1640 (Sigma, USA).  Meanwhile, 
the stock and sub-stock solutions were prepared 
as above.  3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), phosphate 
buffered saline (PBS), Dulbecco’s Modified 
Eagle Medium (DMEM), Bovine Serum 
Albumin (BSA), Tris, dimethyl sulphoxide 
(DMSO), triton X-100, EDTA, RNase A 
and propidium iodide (PI)  were purchased 
from Sigma.  Foetal bovine serum (FBS) was 
purchased from PAA, ammonium chloride and 
sodium citrate from Fisher (UK), Interleukin 
2 and Interleukin 12 Instant Enzyme Link 
Immunosorbent Assay (ELISA) kit from Bender 
MedSystems, Austria, and Ficoll-Paque Plus 
from Amersham Biosciences.
Preparation of Mice Splenocytes and 
Thymocytes Cell Suspensions
Imprinting Control Region (ICR) mice, aged 
5-8 weeks old, were used in all the experiments 
of this study.  The animals were purchased 
from Animal House, the Faculty of Veterinary 
Medicine, Universiti Putra Malaysia.  The 
animals were housed under standard conditions 
at 25 ± 2°C and fed with standard pellets and 
tap water.  The mice were avoided from stress 
or specific control.  This work had earlier been 
approved by Animal Care and Use Committee, 
Universiti Putra Malaysia (UPM), (Ref: UPM/ 
FPV/ PS/ 3.2.1.551/ AUP-R2).
The procedure for preparing mice thymus 
and spleen cell suspensions is quite similar. 
The mice were killed by cervical dislocation. 
The thymus (located above the heart) and the 
spleen (located right behind the liver) were 
removed and quickly washed with HANKS 
Balance Salt Solution (HBSS) (Sigma, USA). 
Then, these thymus and spleen were minced 
and pressed through a sterile wire mesh screen 
(80μm) using a rubber syringe plunger.  The cell 
suspension was washed with PBS (Sigma, USA), 
supplemented with 0.1% BSA (Sigma, USA) and 
0.06% sodium citrate (Fisher, UK) (PBS-BSA-
SC) and spun down at 200 x g for ten minutes. 
The additional step in preparing the spleen cell 
suspension was the splenocytes which were spun 
down with 5 mL lysis buffer (7.56g ammonium 
chloride (Fisher, UK) with 2.42g of Tris (Sigma, 
USA) in 1L distilled water) to lyse the red blood 
cells.  The supernatants were discarded and 4mL 
of Dulbecco’s Modified Eagle Medium (DMEM) 
(Sigma, USA) with 10% heat inactivated FBS 
(PAA, Austria) were added.  The spleen and 
thymus pellet was resuspended and cell counting 
was performed to determine the lymphocyte cell 
number in the suspensions.
Isolation of Peripheral Blood Mononuclear 
Cells (PBMC)
Venous blood (20-25mL) was aseptically 
collected from 20 healthy donors in preservative 
free heparin tubes.  The blood was diluted 
with phosphate buffered saline (PBS), pH 
7.4 and layered onto Ficoll plus at the ratio 
of diluted blood with Ficoll 2:1 (Amersham). 
After centrifugation at 400 x g for 50 min, the 
lymphocytes were collected at the interface and 
washed three times with the PBS.  The cells were 
resuspended in DMEM with 10% foetal bovine 
serum and antibiotics.
MTT Cell Viability Assay
The effects of the compound on the cell 
proliferation of mice splenocytes, thymocytes 
and human PBMC were first determined 
using a colorimetric technique, which is 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) assay (Yeap et 
al., 2007).  Briefly, 100 μL of DMEM media 
with 10% of FBS was added into the all the 
wells, except row A in the 96-well plate (TPP, 
Switzerland).  Then, 100 μL of diluted compound 
at a concentration of 60 μg /mL was added into 
row A and row B.  A series of twofold serial 
dilution of compound was carried out down from 
row B until row G.  Nonetheless, row H was left 
untouched and the excess solution (100 μL) was 
discarded.  100 μL of the cells (mice thymocytes, 
human PBMC, HL60 or NIH3T3), with the cell 
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concentration at 4 × 105 cells/mL, was then 
added into all the wells in the 96-well plate and 
incubated in 37°C, 5% CO2 and 90% humidity 
incubator for selected periods of 24, 48 and 72 h. 
After the corresponding periods (either 24, 48, 
or 72 h), 20 μL of MTT (Sigma, USA) at 5 mg/
mL was added into each well in the 96-well plate 
and incubated for 4 h in 37°C, 5% CO2 and 90% 
humidity incubator.  The medium with MTT was 
removed from every well and 100 μL DMSO 
(Sigma, USA) was then added into each well to 
solubilise the formazan crystal and incubated for 
20 min in 37°C, 5% CO2 incubator.  Finally, the 
plate was read at 570 nm using μ Quant ELISA 
Reader (Bio-Tek Instruments, USA).  The 
results of the compound were compared with 
the result of ConA (1 μg/mL) and LPS (1 μg/
mL) for immunomodulation as a control.  Each 
compound and control was assayed in triplicate 
for three times.  The percentage of proliferation 
was calculated by using the following equation:
% Proliferation = [OD sample – OD control] X 100
                                   OD control
Flow Cytometer Analyses
Flow cytometer was used to support the effect 
of betulinic acid on human PBMC cell cycle 
progression (Alitheen et al., 2001).  PBMC was 
chosen to evaluate the capability of betulinic 
acid to stimulate the proliferation of lymphocytes 
in vitro.  In this study, PWM was used as a 
positive control.  The active concentration 
chosen for the betulinic acid and PWM to 
stimulate the proliferation of PBMC was 30 µg/
mL and 50 µg/mL, respectively.  In this study, 
1 mL of PBMC, with a density of 4 × 105 cells/
mL, was treated with 1 mL of betulinic acid 
and PWM, respectively, according to their 
active concentrations as mentioned above. 
The treatment was carried out in 6 well plates 
(Nunc, UK) with the total working volume of 2 
mL for each well.  The treated cells were then 
incubated for 24, 48 and 72 h and harvested by 
centrifugation at 1000 rpm (200 x g) for 10 min. 
Subsequently, the treated cells were fixed with 
80% ethanol at -20oC for 2 h.  Then, the cells 
were spun down and washed twice with PBS 
pH7.5.  The cell pellets were finally dissolved 
and stained in PBS buffer consisting 0.1% triton 
X-100 (Sigma, USA), 10 mM EDTA (Sigma, 
USA), 50 µg/mL RNase (Sigma, USA) and 3 
µg/mL propidium iodide (PI) (Sigma, USA). 
This process was done in the dark because 
PI is sensitive to light.  The cells were then 
incubated for 30 min in 4oC and analyzed using 
the COULTER EPICS ALTRA flow cytometer 
(Beckman Coulter, USA) at the Laboratory of 
Biologic, Faculty of Veterinary Medicine, UPM, 
within 24 h.
Cytokine Production of Human Peripheral 
Blood Mononuclear Cells
The expressions of extracellular IL-2 and IL-
12 were performed by using Cytokine Instant 
Enzyme Link Immunosorbent Assay (ELISA) 
kit (Bender MedSystems, Austria) (Yeap et al., 
2007).  Briefly, the extracted human PBMC, with 
a cell concentration at 5 X 105 cells /mL, was 
treated with same volume of compound at 30 μg 
/mL in 6 well culture plates (TPP, Switzerland). 
The control cultures, without compound and 
positive control with Pokeweed Mitogen (50 µg/
mL), were prepared simultaneously.  The culture 
was then incubated for respective time periods 
of 24 hours, 48 hours, and 72 hours.  After the 
corresponding period, the samples were washed 
and pelleted.  50 µL of the supernatant was added 
into the strip on the plate of the kit and incubated 
for three hours by shaking at 200 rpm.  Then, 
the sample was washed and immediately added 
with 3,3’,5,5’’-tetramethylbenzidine (TMB) 
Peroxidase substrate in the dark.  Finally, 1M 
Phosphoric acid stop solution was added and 
the plate was read at 450 nm and 620 nm as 
reference wavelength using µ Quant ELISA 
Reader (Bio-Tek Instruments, USA) at the 
Animal Tissue Culture Laboratory, FBBS, 
UPM.  The result was compared to the control 
strip in the kit.  Each compound and control was 
assayed in triplicates.  Meanwhile, the data were 
expressed as pg /mL.
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Statistical Analysis
All the experiments were performed in triplicates. 
The results were analysed by using SPSS version 
13 and expressed as mean ± standard error 
(SE).  The differences between the means were 
evaluated using the ANOVA test (one way), 
followed by the Duncan test and P < 0.05 was 
taken as statistically significant.
RESULTS
Mitogenic Activity of Betulinic Acid on Mice 
Thymocytes
Betulinic acid was demonstrated to stimulate 
the proliferation of mice thymocytes in a time 
and dose-dependent fashion (Fig. 1).  The 
proliferation rate of mice thymocytes treated 
with betulinic acid was less than that of Con A 
after 24 and 48 h of incubation period.  In fact, 
betulinic acid has also been shown to inhibit 
mice thymocytes at a concentration more than 
15 µg /mL after 72 h of treatment.  These data 
revealed that betulinic acid was toxic towards 
mice thymocytes at the concentrations higher 
than 15 µg /mL.  However, it has also been 
shown to stimulate better proliferation of mice 
thymocytes at the concentration of 7.5µg /mL 
throughout the treatment periods.  In more 
specific, betulinic acid demonstrated a better 
proliferation of mice thymocytes compared to 
Con A after 72 h of treatment at the concentration 
of 7.5 µg/mL with the value of 60.3% and 
29.3%, respectively.  This clearly indicates that 
betulinic acid has the capacity to stimulate mice 
thymocytes in a dose-dependent fashion at 24, 
48 and 72 hours.
Mitogenic Activity of Betulinic Acid on Mice 
Splenocytes
As shown in Fig. 2, betulinic acid stimulated the 
proliferation of mice splenocytes in a time and 
dose-dependent fashion.  At 24 h of treatment, 
the proliferation effects of betulinic acid 
increased significantly with a concentration up 
to 14.99% at 30 µg /mL. After 48 h or treatment, 
however, betulinic acid was found to be toxic 
Fig. 1: The effects of betulinic acid on the proliferative response of mice thymocytes 
at 24, 48 and 72h of treatments.  Data represent the means ± SE of triplicate 
determinations from three independent experiments.  The values were the means ± SE 
of three experiments.  The differences between the control and treated group were 
determined by one-way ANOVA (*P < 0.05) and the significant data were marked 
with *
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towards mice splenocytes at a concentration 
higher than 15 µg /mL; nonetheless, it induced 
proliferation at a concentration lower than that. 
On the other hand, betulinic acid inhibited 
mice splenocytes proliferation after 72 h of 
treatment at a concentration higher than 7.5 
µg /mL.  Nevertheless, it showed the highest 
proliferation of mice splenocytes up to 50.77% 
at this concentration.
Mitogenic Activity of Betulinic Acid on Human 
Peripheral Blood Mononuclear Cells (PBMC)
Betulinic acid was shown to stimulate the 
proliferation of PBMC throughout the treatment 
periods (Fig. 3).  It did not inhibit PBMC at all the 
concentrations tested.  Meanwhile, the highest 
proliferation response of the PBMC treated 
with betulinic acid was 33.72%.  Subsequently, 
the proliferation response of betulinic acid 
increased significantly with the increase of the 
concentrations.  At 24 h of treatment, betulinic 
acid exhibited better proliferation of PBMC 
when compared to the positive control, PWM. 
However, the proliferation response of the 
PBMC treated with betulinic acid was less than 
that of the PWM after 48 and 72 h of treatments. 
The data obtained showed that betulinic acid 
stimulated better proliferation of PBMC at 
24 h of treatment and was able to sustain for 
longer incubation time.  PWM exhibited a 
better proliferation of PBMC after 48 and 72 h 
of incubations.
Flow Cytometry Analysis of Cell Cycle 
Distributions on PBMC Based on Proliferation 
Effect of Betulinic acid and PWM at 24, 48 
and 72 h of Incubation Time
As illustrated in Table 1, betulinic acid stimulated 
a higher percentage of cells proliferation at 24 h 
of treatment compared to the untreated cells that 
Fig. 2: The effects of betulinic acid on the proliferative response of mice splenocytes 
at 24, 48 and 72 h of treatment.  Data represent the means ± SE of triplicate 
determinations from three independent experiments.  The values were the means ± SE 
of three experiments.  The differences between the control and treated group were 
determined by one-way ANOVA (*P < 0.05) and the significant data were marked 
with *
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entered G2/M with value of 45.28% and 4.63%, 
respectively.  This result indicated that the treated 
cells were 10 folds higher in their cell number 
compared to the untreated ones.  The cells treated 
with betulinic acid for 48 and 72 h also showed 
better proliferation with the value of 1.2 folds 
and 2.5 folds higher, respectively, as compared to 
the untreated ones.  Nonetheless, the percentage 
of the cells stimulated to proliferate was found 
to be significantly reduced after 48 and 72 h of 
treatment with the value of 44.53% and 38.05%, 
respectively, as compared to those undergoing 24 
h of treatment.  The reduction of the cells that 
entered G2/ mitosis corresponded to an increase 
of cells entering the apoptosis Sub G1 phase. 
The data indicated that a longer exposure time 
to betulinic acid might cause apoptosis to PBMC 
up to 5.76% at 72 h treatment.
The Production of Human Interleukin-2 and 
Human Interleukin-12
To analyze whether betulinic acid enhanced 
or suppressed the production of cytokines, the 
modulatory effect in inducing both human IL-2 
and human IL-12 upon stimulation of PBMC 
was evaluated by using ELISA.
Betulinic acid demonstrated a better 
induction of human IL-2 after 24 h with 9.6 
fold higher compared to the control (Fig. 4). 
This figure showed that it decreased dramatically 
to 2.5 folds and 1.3 folds, respectively, after 
48 and 72 h of the treatment.  However, PWM 
showed a better induction of human IL-2 
after 48 h treatment with 25.33 fold higher 
compared to the control.  In addition, it was also 
demonstrated that there was a stable induction 
of human IL-2 throughout the treatment period. 
Betulinic acid was also shown to induce the 
Fig. 3: The effects of betulinic acid on the proliferative response of human peripheral 
blood mononuclear cells (PBMC) at 24, 48 and 72 h of treatment.  Data represent 
the means ± SE of triplicate determinations from three independent experiments.  The 
values were the means ± SE of three experiments.  The differences between the control 
and treated group were determined by one-way ANOVA (*P < 0.05) and the significant 
data were marked with *
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production of human IL-2 in a time-dependent 
fashion.  The data obtained also indicated that 
those compounds had significantly decreased 
the induction of human IL-2 after 48 and 72 h of 
incubations.  In contrast, the induction of human 
IL-2 was increased by PWM in a time-dependent 
manner, which was shown to induce higher 
production of human IL-2 at 48 h of incubation 
and decreased slightly after 72 h of the treatment, 
with the value of 506.66 pg /mL and 466.66 pg 
/mL, respectively.
In addition, betulinic acid also induced the 
production of human IL-12 in a time-dependent 
fashion.  It significantly increased the production 
of human IL-12 from 24, 48 and 72 h with the 
value of 40 pg /mL, 56.66 pg /mL and 69 pg /
mL, respectively, indicating 3.3 folds, 4.72 folds 
and 5.72 folds higher compared to the negative 
control (Fig. 5).  However, the production of 
human IL-12 induced by LPS decreased sharply 
after 48 and 72 h, with the value of 26.93 pg /
mL or 2.24 folds and 22.06 pg /mL or 1.8 folds 
higher, respectively, compared to the negative 
control.
DISCUSSION
The in vitro immunomodulatory study showed 
that betulinic acid was able to stimulate mice 
thymocytes, mice splenocytes and PBMC in 
a time and dose-dependent fashion.  These 
results are similar to those of Yun et al. (2003), 
whereby a high concentration of betulinic acid 
(i.e. more than 10 µg/mL) caused the cytotoxic 
effect towards mice splenocytes after 72 h of the 
incubation period.  Based on the proliferation 
effect from both the cells (thymocytes and 
spleenocytes), it has been clearly shown that 
betulinic acid is more active towards mice 
thymocytes as compared to mice splenocytes and 
Fig. 4: The production of human IL-2 in culture supernatants upon the stimulation 
of PBMC by betulinic acid and PWM.  PBMC were isolated and incubated at 24, 48 
and 72 h with active concentrations (betulinic acid at 7.5 µg /mL; PWM at 50 µg /mL) 
and IL-2 induction was specifically determined by ELISA.  The values obtained were 
the means ± SE of three experiments.  The differences between the control and treated 
group were determined by one-way ANOVA (*P < 0.05) and the significant data were 
marked with *
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a higher proliferation rate at the concentrations 
of 7.5 µg/mL and above has also been obtained. 
Betulinic acid was able to stimulate 
the proliferation of PBMC without causing 
cytotoxicity at all the concentrations tested 
throughout the treatment periods.  At 24 and 48 h 
of treatment, betulinic acid exhibited to be more 
active at a higher concentration (30 µg /mL) with 
the proliferation rate of more than 20%.  The 
same pattern of lymphocytes proliferation with 
mice thymocytes and mice splenocytes could 
be clearly seen as betulinic acid exhibited to 
be more active at the concentration of 7.5 µg /
mL after 72 h of treatment.  This result clearly 
indicates that betulinic acid tends to induce T 
cells compared to B cells since the population 
of T cells in PBMC is about 90% compared 
to B cells which has only 10% of the PBMC 
population (Cerqueira et al., 2004).  This result 
is also supported by the capability of betulinic 
acid to stimulate higher production of mice 
thymocytes (which produce only T cells) and 
thus supports the preferences of betulinic acid 
to stimulate T cells compared to B cells.
The cell cycle profile of PBMC treated with 
betulinic acid was then evaluated by using flow 
cytometer.  In this cell cycle analysis, it was 
clearly indicated that half of the lymphocytes 
treated with betulinic acid entered G2 and 
Mitosis phase (G2/M) after 24 h treatment. 
However, the percentage of lymphocytes 
entering the G2/M phase was reduced slowly 
after 48 and 72 h of treatment, and this was due 
to the increase in lymphocytes entering the Sub 
G1 phase.  Based on the combination results of 
the total population increase in the MTT assay 
and high population of cell under the G2/M 
phase, it was clearly demonstrated that betulinic 
acid was able to stimulate the proliferation of 
human lymphocytes (PBMC) with less toxicity 
Fig. 5: The production of human interleukin-12 in culture supernatants upon 
stimulation of PBMC by betulinic acid and LPS.  PBMC were isolated and incubated 
at 24, 48 and 72 h with active concentrations (betulinic acid at 7.5 µg /mL; LPS 1 µg/
mL) and IL-12 induction was specifically determined by ELISA.  The values were the 
means ± SE of three experiments.  The differences between the control and treated 
group were determined by one-way ANOVA (*P < 0.05) and the significant data were 
marked with *
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effect even for a longer incubation time.  The 
result from the cell cycle analysis did support 
the result from MTT lymphocytes proliferation 
assay on PBMC.  The less toxicity effect of 
betulinic acid towards normal lymphocytes is 
in agreement with the previous finding by Zuco 
et al. (2002) who showed that peripheral blood 
lymphoblasts were resistant against betulinic 
acid treatment in vitro. 
Cytokines are soluble glycoproteins which 
are involved in the immune response activity. 
The functions of these proteins are diverse, and 
these include regulating the proliferation and 
differentiation of lymphocytes (Stanilove et al., 
2005).  A study on cytokines demonstrated that 
betulinic acid induced the production of human 
IL-2 and the production of human IL-12 in a 
time-dependent fashion.  Meanwhile, betulinic 
acid was showed to induce a higher production 
of human IL-2 after 24 h treatment and the 
production of IL-2 was reduced dramatically 
after 48 and 72 h of treatment.  The pattern of 
betulinic acid in inducing the production of IL-2 
is quite similar with the pattern of the MTT result 
of lymphocytes proliferation assay and cell cycle 
analysis on PBMC, which showed that betulinic 
acid was more active after 24 h of the treatment. 
Meanwhile, it could be speculated that the higher 
induction of IL-2 by betulinic acid was due 
to the capability of betulinic acid to stimulate 
the proliferation of T lymphocytes in both the 
experiments on MTT lymphocytes proliferation 
assay and cell cycle study.  Furthermore, the 
induction of IL-2 by betulinic acid is relevant 
to this study since that IL-2 has been known 
as a central cytokine in the regulation of T cell 
responses (Ghosh et al., 1999).  In addition, 
the populations of T and B lymphocytes in the 
human peripheral blood lymphocytes, where 
90% T cell and only 10% B cell (Cerqueira et 
al., 2004) may contribute to a higher production 
of human IL-2 in culture supernatant treated with 
betulinic acid.
In contrast, betulinic acid was demonstrated 
to induce the production of human IL-12 
in a time-dependent fashion.  IL-12 is also 
known as pleiotropic cytokine with important 
proinflammatory cytokine and immunoregulatory 
functions.  It plays a key role in the modulation 
of the immune response by providing the stimuli 
for the differentiation of CD4+ T cells into Th1 
and IFN-γ secreting cells.  IL-12 is released 
during the early stages of infections caused by a 
large variety of bacteria, intracellular pathogens, 
fungi, and certain viruses.  The early production 
of IL-12 is T cell independent which is caused by 
direct interaction of pathogens or their products 
with phagocytic cells (Trinchieri et al., 2003).
The capability of betulinic acid to induce the 
low concentration of human IL-12 is  relevant 
since this compound has been reported to 
modulate the Th1/Th2 cells to produce IL-2 and 
IL-12 cytokines, which are the groups of Th1 as 
well as IL-10 anti-inflammatory cytokines, which 
is the group of Th2 (Zdzisińska et al., 2003).  In 
a similar experiment, Zdzisińska et al. (2003) 
demonstrated that betulinic acid did not influence 
TNF-α production, a proinflammatory cytokine. 
In addition, betulinic acid has also been known 
to be effective as an anti-inflammatory agent in 
various experiment systems (e.g. Mukherjee et 
al., 1997; Bernard et al., 2001).  The capability 
of betulinic acid to induce small amount of 
IL-12 production is in agreement with the 
previous studies which have discovered that 
betulinic acid is an effective anti-inflammatory 
agent.  Therefore, the evidence indicating that 
betulinic acid induces low concentrations of 
IL-12 and TNF-α suggests the involvement 
of NF-қB signal transduction pathway, which 
positively regulates proinflammatory cytokine 
gene expression.
CONCLUSION
Although betulinic acid has shown encouraging 
results as an immunomodulator, further studies 
are still needed to elucidate the exact mechanism 
involved in betulinic acid.  Once the mechanism 
of its action and comprehensive bioassay are 
elucidated, betulinic acid can be used as a lead 
molecule for the new generation of drugs in 
cancer treatment, particularly in boosting up the 
immune system.
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